

# EVALUATION ADVISORY COMMITTEE CHAIR REPORT



BOARD MEETING  
**James Hargreaves**  
7-8 December 2022, Geneva,  
Switzerland

[gavi.org](https://gavi.org)



# Overview: Gavi 5.0 multi-year evaluation workplan

EVALUATION	YEAR				
	2021	2022	2023	2024	2025
COVAX Facility and COVAX AMC formative and baseline Study		◆	◆		
Evaluation of Gavi's initial response to COVID-19	◆	◆			
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities		◆	◆	◆	◆
Evaluation of the operationalisation of Gavi's strategy through Gavi's policies, programmatic guidance and use of funding levers		◆	◆		
Mid Term Evaluation (MTE) of Gavi's 2021-2025 Strategy		◆	◆	◆	◆
Gavi's contribution to sustainability of coverage post-transition				◆	◆
COVAX Facility and COVAX AMC multi-stage evaluation					

	Evaluation commissioning period
	Evaluation implementation and delivery period
◆	Deliverable that needs to be seen by the EAC

# Baseline Study and Formative Review – COVAX Facility and COVAX AMC

Evaluation	Guidance	Next steps
COVAX Facility and COVAX AMC baseline study and formative review	<ul style="list-style-type: none"><li>• Ensure a transparent and justifiable linkage between the primary data collected / collated, the analysis process and the evaluation findings, conclusions, lessons and recommendations;</li><li>• Provide evaluative conclusions with a critical lens, including in the high-level conclusions and recommendations;</li><li>• Transparently reflect divergence of opinion in the final report at all levels of input and feedback from stakeholders, and, with the EAC's backing, hold the line on scope of the evaluation</li><li>• The next phase of COVAX evaluation should ensure it evaluates the causal connections in the Theory of Change</li></ul>	<ul style="list-style-type: none"><li>• Draft final report due early December</li></ul>

# Gavi's initial response to COVID-19

Evaluation	Guidance	Next steps
Evaluation of Gavi's initial response to COVID-19	<ul style="list-style-type: none"><li>• Ensure a transparent and robust linkage between the primary data collected/collated, the analysis process and the evaluation findings, conclusions, lessons, and recommendations;</li><li>• MEL develop a system to prospectively assess likely data needs and formulate a plan in relation to strengthening data systems that will be of value to evaluations when these are being considered/developed, in order to avoid evaluations needing to conclude that "data wasn't available"</li><li>• To strengthen utility: Target recommendations to 5.1; contextualise with COVAX; and consider how to best put evaluation results before the Board, keeping in mind the Mid Term Evaluation and 5.1</li></ul>	<ul style="list-style-type: none"><li>• Final report to be published following completion of the Evaluation Management Response process</li></ul>



# Zero Dose

Evaluation	Guidance	Progress Update
<p>Evaluation of Gavi's contribution to reaching zero-dose children and missed communities</p>	<ul style="list-style-type: none"><li>• Proceed with the proposal to appoint a Steering Committee including the secondment of two EAC members</li><li>• Zero-Dose evaluators should develop a more detailed design and analytic plan, for review by the Steering Committee/EAC within the inception report.</li></ul>	<ul style="list-style-type: none"><li>• Evaluation commenced in September and draft inception report has been shared with relevant stakeholders for review</li><li>• Inception report review: Further work needed on the evaluation design, framework and methodology is required, especially the Theory of Change and effectiveness evaluation methods</li><li>• Data collection to commence in early Q1 2023 with a draft report due late Q2 2023</li></ul>

# Other evaluations

Evaluation	Progress Update
Evaluation of the operationalisation of Gavi's strategy through Gavi's policies, programmatic guidance and use of funding levers	<ul style="list-style-type: none"><li>• Evaluation commenced in September and the inception report has reviewed by relevant stakeholders</li><li>• Data collection is ongoing with a draft report expected early Q2 2023</li></ul>
Mid Term Evaluation (MTE) of Gavi's 2021-2025 Strategy	<ul style="list-style-type: none"><li>• Evaluation commenced in mid-October and draft inception report has been shared with relevant stakeholders for review</li><li>• Draft interim report due mid-Q3 2023 following publication of WUENIC data</li></ul>
Gavi's contribution to sustainability of coverage post-transition	Timeline TBC – for discussion with EAC in 2023
COVAX Facility and COVAX AMC multi-stage evaluation	Evaluability Assessment and Evaluation Design Study proposes: <ul style="list-style-type: none"><li>• Multi-stage evaluation design over 10-year horizon, blending principles of both 1) periodic and phased formative-summative evaluation, and 2) real-time evaluation</li><li>• Formative review and baseline study ongoing till Q1 2023</li><li>• Secretariat is currently developing the Terms of Reference to be discussed at the next EAC meeting in March 2023</li></ul>

# Evaluation Function Review

Session	Guidance
<ul style="list-style-type: none"><li>• Review of Evaluation Function</li></ul>	<ul style="list-style-type: none"><li>• The EAC expressed concern that proposed structural changes appear to bring more negatives than positives</li><li>• Proposed that Gavi Management not implement structural changes until after MOPAN review concludes; and requested that the MOPAN evaluation have an enhanced focus on evaluation and the EAC would like to be assured that its consensus view about direction of travel will be shared with the evaluators</li><li>• Advised to proceed with implementing the mitigation measures that are immediately actionable, with the exception of EAC participation in co-creation workshops</li><li>• Advised to avoid the EAC getting pulled into management activities and focus on its advisory / governance role.</li></ul>

# EAC practice

Session	Guidance
<ul style="list-style-type: none"><li>EAC Engagement</li></ul>	<ul style="list-style-type: none"><li>To allow EAC focal points and EAC Steering Committee members the opportunity to advise on the presentation of evaluation findings, particularly in the case of interim findings, in the lead up to Governance meetings, as appropriate (with a particular focus on COVAX evaluation and COVID-19 evaluation over coming 6 months, including in upcoming PPC papers).</li></ul>
<ul style="list-style-type: none"><li>Revised Evaluation Policy</li></ul>	<ul style="list-style-type: none"><li>Supplier review: Update and provide experience in relation to each item on recommended actions; work with EAC members to look at barriers and define what success might look like.</li><li>EAC members sitting on steering committees. Conduct a light touch after action review, and discuss at the March 2023 EAC meeting;</li><li>One Steering Committee member per evaluation will act as convener to coordinate interaction between the EAC between meetings.</li><li>Not to pursue Vice-Chair role; and</li><li>Continue to discuss options for strengthening engagement with PPC.</li></ul>



# Thank you